Logo image of WINT

WINDTREE THERAPEUTICS INC (WINT) Stock Fundamental Analysis

NASDAQ:WINT - Nasdaq - US97382D6004 - Common Stock - Currency: USD

0.6001  -0.08 (-11.11%)

After market: 0.61 +0.01 (+1.65%)

Fundamental Rating

1

Overall WINT gets a fundamental rating of 1 out of 10. We evaluated WINT against 553 industry peers in the Biotechnology industry. WINT has a bad profitability rating. Also its financial health evaluation is rather negative. WINT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year WINT has reported negative net income.
In the past year WINT has reported a negative cash flow from operations.
WINT had negative earnings in each of the past 5 years.
WINT had a negative operating cash flow in each of the past 5 years.
WINT Yearly Net Income VS EBIT VS OCF VS FCFWINT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of WINT (-77.52%) is worse than 68.72% of its industry peers.
WINT has a Return On Equity of -183.17%. This is in the lower half of the industry: WINT underperforms 65.28% of its industry peers.
Industry RankSector Rank
ROA -77.52%
ROE -183.17%
ROIC N/A
ROA(3y)-85.45%
ROA(5y)-61.66%
ROE(3y)-383.83%
ROE(5y)-246.99%
ROIC(3y)N/A
ROIC(5y)N/A
WINT Yearly ROA, ROE, ROICWINT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WINT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WINT Yearly Profit, Operating, Gross MarginsWINT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, WINT has more shares outstanding
WINT has more shares outstanding than it did 5 years ago.
WINT has a better debt/assets ratio than last year.
WINT Yearly Shares OutstandingWINT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
WINT Yearly Total Debt VS Total AssetsWINT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

WINT has an Altman-Z score of -47.45. This is a bad value and indicates that WINT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -47.45, WINT is doing worse than 92.77% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that WINT is not too dependend on debt financing.
WINT has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -47.45
ROIC/WACCN/A
WACCN/A
WINT Yearly LT Debt VS Equity VS FCFWINT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

WINT has a Current Ratio of 0.25. This is a bad value and indicates that WINT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.25, WINT is not doing good in the industry: 94.39% of the companies in the same industry are doing better.
A Quick Ratio of 0.25 indicates that WINT may have some problems paying its short term obligations.
WINT's Quick ratio of 0.25 is on the low side compared to the rest of the industry. WINT is outperformed by 94.03% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
WINT Yearly Current Assets VS Current LiabilitesWINT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

1

3. Growth

3.1 Past

The earnings per share for WINT have decreased strongly by -236.14% in the last year.
EPS 1Y (TTM)-236.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.49% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.67%
EPS Next 2Y41.23%
EPS Next 3Y25.96%
EPS Next 5Y14.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WINT Yearly Revenue VS EstimatesWINT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2022 2030 2031 50M 100M 150M 200M
WINT Yearly EPS VS EstimatesWINT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -200K -400K -600K -800K -1M

1

4. Valuation

4.1 Price/Earnings Ratio

WINT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WINT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WINT Price Earnings VS Forward Price EarningsWINT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WINT Per share dataWINT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

A more expensive valuation may be justified as WINT's earnings are expected to grow with 25.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.23%
EPS Next 3Y25.96%

0

5. Dividend

5.1 Amount

WINT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

WINDTREE THERAPEUTICS INC

NASDAQ:WINT (8/1/2025, 8:10:57 PM)

After market: 0.61 +0.01 (+1.65%)

0.6001

-0.08 (-11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-16 2025-05-16/amc
Earnings (Next)08-18 2025-08-18/amc
Inst Owners1.24%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap7.15M
Analysts43.33
Price Target180.54 (29984.99%)
Short Float %21.84%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.21
Dividend Growth(5Y)N/A
DP-3.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-400
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS0
BVpS0.95
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.52%
ROE -183.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.45%
ROA(5y)-61.66%
ROE(3y)-383.83%
ROE(5y)-246.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -47.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.35%
Cap/Depr(5y)88.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-236.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.42%
EPS Next Y84.67%
EPS Next 2Y41.23%
EPS Next 3Y25.96%
EPS Next 5Y14.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.92%
OCF growth 3YN/A
OCF growth 5YN/A